Locations:
Min Investment:
Max Investment:
Target Investment:
2016
2016
Investing broadly in private healthcare companies with an interest in biotech
2024
2021
2021
Discovering and developing novel antibody drug conjugate antibody therapies in oncology
2019
Essential Access Health (formerly California Family Health Council) is a non-profit organization that champions and promotes quality sexual and reproductive health care for all. Essential Access Health achieves its mission through an umbrella of services including advanced clinical research, provider training, patient education and consumer awareness, public policy and clinic support initiatives. As the administrator of the nation's largest Title X federal family planning program, we partner with a diverse provider network that collectively serves nearly one million women, men and teens annually at more than 340 health centers in 37 of California's 58 counties.
2022 - 2024
2022 - 2024
Confluence Therapeutics is pioneering a novel platform of RNA binding protein targeted oligonucleotide therapeutics for therapeutic areas with significant unmet need.
2017 - 2023
2017 - 2023
2018 - 2020
2018 - 2020
Microbial cell therapy for diseases with high unmet medical need
2009 - 2016
2015 - 2016
Responsible for leading the marketing team for rucaparib, a PARP inhibitor for the treatment of advanced ovarian cancer. Rucaparib received breakthrough therapy designation from the FDA in 2015 and NDA filing is expected mid-2016.
2009 - 2016
Responsible for the in-licensing of the current Clovis pipeline, including: global rights to rociletinib (CO-1686) from Avila Therapeutics (now Celgene), rucaparib (CO-338) from Pfizer, and US and Japanese right to lucitanib from EOS.
2006 - 2009
2006 - 2009
2005 - 2006
2005 - 2006